Evidence map›Paper›PMID 30155031›Full record

ArticleChemical science2016

The creation and characterisation of a National Compound Collection: the Royal Society of Chemistry pilot.

David M Andrews, Laura M Broad, Paul J Edwards, David N A Fox, Timothy Gallagher, Stephen L Garland, Richard Kidd, Joseph B Sweeney

Open access · diamondAbstract read
In one paragraph

Article in Chemical science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

David M AndrewsRoyal Society of Chemistry , Thomas Graham House, Science Park, Milton Road , Cambridge , CB4 0WF , UK . Email: david.andrews@astrazeneca.com.ORCID 0000-0002-6716-6270
Laura M BroadSchool of Chemistry , University of Bristol , Bristol , BS8 1TS , UK.ORCID 0000-0003-0442-4698
Paul J EdwardsScicate Limited , Mendip Court , Bath Road , Wells , Somerset BA5 3DG , UK.
David N A FoxRoyal Society of Chemistry , Thomas Graham House, Science Park, Milton Road , Cambridge , CB4 0WF , UK . Email: david.andrews@astrazeneca.com.
Timothy GallagherSchool of Chemistry , University of Bristol , Bristol , BS8 1TS , UK.ORCID 0000-0002-3544-327X
Stephen L GarlandNQuiX Ltd , Causeway House, Dane Street , Bishops Stortford , Hertfordshire CM23 3BT , UK.ORCID 0000-0002-7411-6319
Richard KiddRoyal Society of Chemistry , Thomas Graham House, Science Park, Milton Road , Cambridge , CB4 0WF , UK . Email: david.andrews@astrazeneca.com.ORCID 0000-0002-4638-5052
Joseph B SweeneyDepartment of Chemical Sciences , University of Huddersfield , Huddersfield HD1 3DH , UK.ORCID 0000-0001-7593-9598
Royal Society of Chemistry · GBUniversity of Bristol · GBTiGenix (Spain) · ESUniversity of Huddersfield · GBWells College · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present a summary of the National Compound Collection (NCC) pilot; which harvested chemical structure data from 746 publicly-available PhD theses to create an enhanced database of diverse and interesting (largely organic) molecular entities. The database comprised ∼75 000 structure entries, of which 70% were new to ChemSpider at the time of upload. The dataset was evaluated for structural uniqueness by twelve external drug discovery groups from the pharmaceutical, biotech, academic and not-for-profit sectors. These partners generated data reported here comparing the NCC pilot with their in-house compound collections. The proportion of NCC structures considered to be useful for drug discovery ranged from 5-80% depending on the strictness of the filters used; most interestingly from a drug discovery standpoint ∼13k NCC compounds (18% of the NCC) passed the filters and were of good diversity. These compounds are quite different from those that are already present in the screening collections but not so different that they are no longer considered to be drug-like. In general, the drug discovery teams would consider these compounds to be high value molecules for inclusion in their screening collections. This pilot addressed the potential value of unpublished data and explored the practicalities of large-scale data extraction, to inform both retrospective and prospective extraction of chemical data from theses.

Identifiers

PMID30155031
PMCPMC6013800
OpenAlexW2286719027

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.